School of Pharmacy, University of Waterloo, Kitchener, ON, N2G 2C5, Canada.
Women's College Hospital, Toronto, ON, Canada.
Syst Rev. 2024 Oct 14;13(1):259. doi: 10.1186/s13643-024-02671-5.
Approximately, 10% of people report a penicillin allergy; however, more than 90% can safely undergo delabeling after a detailed history, oral challenge, or other investigations such as penicillin skin testing (PST). Although PST is the gold standard, the results can be heterogeneous, and awaiting specialist assessment may take an inordinate amount of time. Therefore, oral provocation challenge has become acceptable for individuals with low-risk penicillin allergy histories. There also appears to be an association with increased prevalence of adverse drug reaction reporting in female individuals, which may translate to penicillin allergy prevalence; however, the evidence has not been assessed through a sex and gender lens. This systematic review will identify and synthesize the findings from studies that report measures of effectiveness and safety of interventions aimed at delabeling penicillin allergies in low-risk individuals. Information related to sex and gender will be extracted, where available, to understand potential differences in allergy reporting and patient outcomes.
The Cochrane Handbook for Systematic Reviews of Interventions and the Centre for Review and Dissemination's Guidance for Undertaking Reviews in Health Care will be used as frameworks for conducting this systematic review. The literature search will be conducted by a medical librarian (B. M. M.) and will consist of a search strategy to identify and retrieve published studies that meet our inclusion criteria. Studies that require penicillin skin testing (PST) as a step prior to other interventions will be excluded. Integrated knowledge translation involving co-design was carried out for this systematic review protocol creation. Data extraction will be conducted at four levels: (1) study level, (2) patient level, (3) intervention level, and (4) outcome level. A narrative descriptive synthesis of results and risk of bias of all included studies will be provided, and, if relevant, a meta-analysis will be performed.
The dissemination of findings from this knowledge synthesis to various stakeholders is intended to inform on options for evidence-based interventions to aid in delabeling penicillin allergies in individuals with a low risk of experiencing a hypersensitivity reaction. Detailed reporting on the characteristics of delabeling interventions as well as the effectiveness of similar interventions will benefit policy makers considering the implementation of a penicillin allergy delabeling protocol. Additionally, findings from this systematic review will report on the current evidence regarding the role of sex and gender in both the prevalence and outcomes associated with the presence of penicillin allergies.
PROSPERO CRD42022336457.
大约有 10%的人报告对青霉素过敏;然而,经过详细的病史询问、口服挑战或其他检查(如青霉素皮试),超过 90%的人可以安全地进行去标签化。尽管青霉素皮试是金标准,但结果可能存在异质性,等待专家评估可能需要很长时间。因此,口服激发挑战已成为低风险青霉素过敏史个体的可接受方法。似乎还存在女性个体中不良反应报告发生率增加与青霉素过敏发生率之间的关联;然而,这方面的证据尚未通过性别视角进行评估。本系统评价旨在确定和综合报告旨在降低低危个体青霉素过敏标签的干预措施有效性和安全性的研究结果。将提取与性别相关的信息(如可用),以了解过敏报告和患者结局方面的潜在差异。
将使用 Cochrane 干预系统评价手册和卫生保健综述中心的指南作为本系统评价的框架。文献检索将由一名医学图书管理员(B. M. M.)进行,检索策略旨在识别和检索符合我们纳入标准的已发表研究。需要进行青霉素皮试(PST)作为其他干预措施之前的步骤的研究将被排除。本系统评价方案的创建涉及共同设计的综合知识转化。数据提取将在四个层面进行:(1)研究层面,(2)患者层面,(3)干预层面和(4)结局层面。将提供所有纳入研究的结果和偏倚风险的叙述性描述性综合,并在相关情况下进行荟萃分析。
本知识综合的发现将传播给各个利益相关者,旨在为具有低过敏反应风险的个体去标签化青霉素过敏的基于证据的干预措施提供信息。详细报告去标签化干预措施的特征以及类似干预措施的有效性将使考虑实施青霉素过敏去标签化方案的政策制定者受益。此外,本系统评价的结果还将报告当前关于性别在青霉素过敏的患病率和结局方面的作用的证据。
PROSPERO CRD42022336457。